leadf
logo-loader
viewReNeuron Group PLC

ReNeuron Group completes first dosing of patients in study for new degenerative eye disease therapy

ReNeuron Group PLC's (LON:RENE) Michael Hunt talks to Proactive London following news on their data from their latest clinical assessment, which will be presented later this year. 

Hunt talks through the phase IIa extension study of its human retinal progenitor cell therapy for degenerative eye disease.

Quick facts: ReNeuron Group PLC

Price: 103.25 GBX

LSE:RENE
Market: LSE
Market Cap: £58.7 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read